Ertugliflozin and combination Tablets

RLD : Motpply XR US
Tech Transfer Readiness- Q2 2027

Under development, The RLD used is Vraylar, Tech transfer readiness Q4 2026, Dossier readiness Q3 2027

RLD used is Zambon and product is available for out-licensing in EU countries and Brazil

Meets the RLD Heptral and Ready for tech transfer, Dossier readiness Q2 2027

Deferasirox Sprinkle granules were developed to improve palatability and patient adherence.
and it is in compliance to EU RLD Jadenu
Dossier Ready for ROW and emerging markets
Dossier Ready for EU- Q2 2027

The API will be used for the development of generic version of Desferal injection 

Rare disease product
Developed in India, a generic version of Endari approved in US

Dossier ready for emerging Markets
Will undergo clinical Trials for sickle cell in Q3 2026

Meets the Japan RLD Kremezin granules, worldwide charcoal tablets are already available. The carbon in granule form is more easy to use
Dossier Readiness Q4 2026

Suxibuzone is an analgesic used for joint and muscular pain. It is a prodrug of the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone,

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

RLD: Subvenite US
Tech Transfer Readiness- Q3 2027
Dossier Readiness Q2 2028

Rajah Dubey, Chief Technical Strategist of SRS Life Sciences, speaks with CPHI TV at CPHI Worldwide in Madrid.